A detailed history of Cutter & CO Brokerage, Inc. transactions in Landec Corp \Ca\ stock. As of the latest transaction made, Cutter & CO Brokerage, Inc. holds 12,334 shares of LNDC stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,334
Previous 10,767 14.55%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
N/A
1,567 Added 14.55%
12,334 $0
Q1 2024

Apr 30, 2024

SELL
N/A
-4,800 Reduced 30.83%
10,767 $0
Q4 2023

Feb 01, 2024

SELL
N/A
-6,133 Reduced 28.26%
15,567 $0
Q4 2022

Feb 03, 2023

SELL
$0.0 - $9.95 $0 - $67,660
-6,800 Reduced 23.86%
21,700 $0
Q2 2022

Jul 28, 2022

SELL
$8.84 - $11.64 $1,768 - $2,328
-200 Reduced 0.7%
28,500 $284,000
Q4 2021

Feb 10, 2022

SELL
$7.95 - $11.24 $27,825 - $39,340
-3,500 Reduced 10.87%
28,700 $319,000
Q2 2020

Aug 10, 2020

BUY
$7.96 - $11.54 $256,312 - $371,588
32,200 New
32,200 $256,000
Q1 2020

May 05, 2020

SELL
$7.69 - $11.68 $247,618 - $376,096
-32,200 Closed
0 $0
Q3 2019

Nov 07, 2019

SELL
$9.66 - $12.36 $4,830 - $6,180
-500 Reduced 1.53%
32,200 $350,000
Q1 2019

Apr 23, 2019

SELL
$10.35 - $13.06 $2,070 - $2,612
-200 Reduced 0.61%
32,700 $402,000
Q3 2018

Oct 12, 2018

BUY
$12.65 - $15.15 $12,650 - $15,150
1,000 Added 3.13%
32,900 $474,000
Q1 2018

May 11, 2018

BUY
$12.0 - $14.45 $81,600 - $98,260
6,800 Added 27.09%
31,900 $416,000
Q4 2017

Jan 30, 2018

SELL
$11.65 - $13.35 $79,220 - $90,780
-6,800 Reduced 21.32%
25,100 $316,000
Q3 2017

Oct 23, 2017

SELL
$11.95 - $13.35 $5,975 - $6,675
-500 Reduced 1.54%
31,900 $413,000
Q2 2017

Aug 07, 2017

BUY
N/A
32,400
32,400 $481,000

Others Institutions Holding LNDC

About LANDEC CORP \CA\


  • Ticker LNDC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 29,595,600
  • Description
  • Landec Corporation operates as a diversified health and wellness company. The company manufactures pharmaceutical-grade sodium hyaluronate (HA)-based biomaterials for primary use in the ophthalmic and orthopedic markets. It also provides product development services to its partners for HA-based, as well as non-HA based, aseptically formulated, a...
More about LNDC
Track This Portfolio

Track Cutter & CO Brokerage, Inc. Portfolio

Follow Cutter & CO Brokerage, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutter & CO Brokerage, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cutter & CO Brokerage, Inc. with notifications on news.